To investigate the effects of dextrose prolotherapy in patients with knee osteoarthritis (KOA).
Design:
A prospective, randomized-controlled interventional trial.
Setting:
An outpatient pain medicine clinic.
Participants:
The study included 66 patients aged 40–70 years with chronic knee pain refractory to conservative therapy and diagnosed as grade II or III KOA according to the Kellgren–Lawrence classification. The patients were assigned to dextrose prolotherapy group (PG; n = 22), saline group (SG; n = 22), or control group (CG; n = 22).
Interventions:
The intra- and extra-articular dextrose prolotherapy and saline injections were administered to the PG and SG, respectively, at 0, 3, and 6 weeks. The patients were blinded to their injection group status. A home-based exercise program was prescribed for all patients in all three groups.
Outcome measures:
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, activity pain, stiffness severity measured using a visual analog scale (VAS), and the health-related quality of life (HRQoL) scores measured using the Short Form-36 (SF-36) subscales were recorded at the baseline, 6-week, and 18-week follow-ups.
Results:
The WOMAC-pain and VAS-activity pain scores decreased significantly in the PG compared to the SG (p = 0.002 and p < 0.001, respectively) and CG (p < 0.001 and p < 0.001, respectively) at 18 weeks. The WOMAC-stiffness scores decreased in the PG compared to the CG at 18 weeks (p < 0.001). The WOMAC physical functioning scores were improved in the PG compared to the CG at 18 weeks (p < 0.001). The physical component scores of the HRQoL were significantly improved in the PG compared to the CG at 18 weeks (p = 0.016), but the mental component scores of the HRQoL showed no significant differences.
Conclusions:
These findings suggest that dextrose prolotherapy is effective at reducing pain and improving the functional status and quality of life in patients with KOA.
Get full access to this article
View all access options for this article.
References
1.
BindawasSM, VennuV, Al SnihS. Differences in health-related quality of life among subjects with frequent bilateral or unilateral knee pain: Data from the Osteoarthritis Initiative study. J Orthop Sports Phys Ther, 2015; 45:128–136.
2.
SharmaL, CahueS, SongJ, et al.Physical functioning over three years in knee osteoarthritis: Role of psychosocial, local mechanical, and neuromuscular factors. Arthritis Rheum, 2003; 48:3359–3370.
3.
FibelKH, HillstromHJ, HalpernBC. State-of-the-art management of knee osteoarthritis. World J Clin Cases, 2015; 3:89–101.
4.
HochbergMC, AltmanRD, AprilKT, et al.American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken), 2012; 64:465–474.
5.
FernandesL, HagenKB, BijlsmaJW, et al.EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis, 2013; 72:1125–1135.
6.
AldermanD. Prolotherapy for musculoskeletal pain. Pract Pain Manag, 2007:10–15.
7.
RabagoD, SlattengrenA, ZgierskaA. Prolotherapy in primary care practice. Prim Care, 2010; 37:65–80.
8.
HauserRA, LacknerJB, Steilen-MatiasD, HarrisDK. A systematic review of dextrose prolotherapy for chronic musculoskeletal pain. Clin Med Insights Arthritis Musculoskelet Disord, 2016; 9:139–159.
9.
Güran Ş, ÇobanZD, Karasimav Ö, et al. Dextrose solution used for prolotherapy decreases cell viability and increases gene expressions of angiogenic and apopitotic factors. Gulhane Med J, 2018; 60:42–46.
10.
JensenKT, RabagoDP, BestTM, et al.Early inflammatory response of knee ligaments to prolotherapy in a rat model. J Orthop Res, 2008; 26:816–823.
11.
JensenKT, RabagoD, BestTM, et al.Longer term response of knee ligaments to prolotherapy in a rat injury model. Am J Sports Med, 2008; 36:1347–1357.
12.
ReevesKD, SitRW, RabagoDP. Dextrose prolotherapy: A narrative review of basic science, clinical research, and best treatment recommendations. Phys Med Rehabil Clin N Am, 2016; 27:783–823.
13.
YoshiiY, ZhaoC, SchmelzerJD, et al.The effects of hypertonic dextrose injection on connective tissue and nerve conduction through the rabbit carpal tunnel. Arch Phys Med Rehabil, 2009; 90:333–339.
14.
YoshiiY, ZhaoC, SchmelzerJD, et al.Effects of multiple injections of hypertonic dextrose in the rabbit carpal tunnel: A potential model of carpal tunnel syndrome development. Hand (N Y), 2014; 9:52–57.
15.
ReevesKD, HassaneinK. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med, 2000; 6:68–79.
16.
TopolGA, PodestaLA, ReevesKD, et al.Chondrogenic effect of intra-articular hypertonic-dextrose (prolotherapy) in severe knee osteoarthritis. PM R, 2016; 8:1072–1082.
17.
HassanF, TrebinjacS, MurrellWD, MaffulliN. The effectiveness of prolotherapy in treating knee osteoarthritis in adults: A systematic review. Br Med Bull, 2017; 122:91–108.
18.
RabagoD, PattersonJJ, MundtM, et al.Dextrose prolotherapy for knee osteoarthritis: A randomized controlled trial. Ann Fam Med, 2013; 11:229–237.
19.
DumaisR, BenoitC, DumaisA, et al.Effect of regenerative injection therapy on function and pain in patients with knee osteoarthritis: A randomized crossover study. Pain Med, 2012; 13:990–999.
20.
AltmanR, AschE, BlochD, et al.Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum, 1986; 29:1039–1049.
21.
KellgrenJH, LawrenceJS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis, 1957; 16:494–502.
22.
BellamyN, KirwanJ, BoersM, et al.Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol, 1997; 24:799–802.
23.
BellamyN, BuchananWW, GoldsmithCH, et al.Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol, 1988; 15:1833–1840.
24.
McConnellS, KolopackP, DavisAM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): A review of its utility and measurement properties. Arthritis Rheum, 2001; 45:453–461.
25.
TüzünE, EkerL, AytarA, et al.Acceptability, reliability, validity and responsiveness of the Turkish version of WOMAC osteoarthritis index. Osteoarthritis Cartilage, 2005; 13:28–33.
26.
CarlssonAM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain, 1983; 16:87–101.
27.
WareJE Jr. SF-36 health survey update. Spine, 2000; 25:3130–3139.
28.
WeiglM, EwertT, KleinschmidtJ, StuckiG. Measuring the outcome of health resort programs. J Rheumatol, 2006; 33:764–770.
29.
WareJE, KosinskiM, KellerSD. SF-36® Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
30.
KocyigitH, AydemirO, FisekG, et al.Validity and reliability of Turkish version of Short-form 36: A study of a patients with rheumatoid disorder. J Drug Ther, 1999; 12:102–106.
31.
KrsticevicM, JericM, DosenovicS, et al.Proliferative injection therapy for osteoarthritis: A systematic review. Int Orthop, 2017; 41:671–679.
32.
NouraniB, RabagoD. Prolotherapy for knee osteoarthritis: A descriptive review. Curr Phys Med Rehab Rep, 2016; 4:42–49.
33.
SitRW, ChungVCH, ReevesKD, et al.Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: A systematic review and meta-analysis. Sci Rep, 2016; 6:25247.
34.
HungCY, HsiaoMY, ChangKV, et al.Comparative effectiveness of dextrose prolotherapy versus control injections and exercise in the management of osteoarthritis pain: A systematic review and meta-analysis. J Pain Res, 2016; 9:847–857.
35.
EhrichEW, DaviesGM, WatsonDJ, et al.Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol, 2000; 27:2635–2641.
36.
RabagoD, KijowskiR, WoodsM, et al.Association between disease-specific quality of life and magnetic resonance imaging outcomes in a clinical trial of prolotherapy for knee osteoarthritis. Arch Phys Med Rehabil, 2013; 94:2075–2082.
37.
RabagoD, ZgierskaA, FortneyL, et al.Hypertonic dextrose injections (prolotherapy) for knee osteoarthritis: Results of a single-arm uncontrolled study with 1-year follow-up. J Altern Complement Med, 2012; 18:408–414.
38.
RabagoD, MundtM, ZgierskaA, et al.Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: Long term outcomes. Complement Ther Med, 2015; 23:388–395.
39.
EslamianF, AmouzandehB. Therapeutic effects of prolotherapy with intra-articular dextrose injection in patients with moderate knee osteoarthritis: A single-arm study with 6 months follow up. Ther Adv Musculoskelet Dis, 2015; 7:35–44.
40.
AltmanRD, DevjiT, BhandariM, et al.Clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. Semin Arthritis Rheum, 2016; 46:151–159.
41.
Bar-OrD, RaelLT, BrodyEN. Use of saline as a placebo in intra-articular injections in osteoarthritis: Potential contributions to nociceptive pain relief. Open Rheumatol J, 2017; 11:16–22.
42.
AngstF, AeschlimannA, StuckiG. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum, 2001; 4:384–391.
43.
McAlindonTE, BannuruRR, SullivanMC, et al.OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage, 2014; 22:363–388.
44.
RabagoD, NouraniB. Prolotherapy for osteoarthritis and tendinopathy: A descriptive review. Curr Rheumatol Rep, 2017; 19:34.
45.
HashemiM, JaliliP, MennatiS, et al.The effects of Prolotherapy with hypertonic dextrose versus Prolozone (intraarticular ozone) in patients with knee osteoarthritis. Anesthesiol Pain Med, 2015; 5:e27585.
46.
FarpourHR, FereydooniF. Comparative effectiveness of intra-articular prolotherapy versus peri-articular prolotherapy on pain reduction and improving function in patients with knee osteoarthritis: A randomized clinical trial. Electron Physician, 2017; 9:5663–5669.
47.
RezasoltaniZ, TaheriM, MofradMK, MohajeraniSA. Periarticular dextrose prolotherapy instead of intra-articular injection for pain and functional improvement in knee osteoarthritis. J Pain Res, 2017; 10:1179–1187.
48.
SitRWS, WuRWK, ReevesKD, et al.Efficacy of intra-articular hypertonic dextrose prolotherapy versus normal saline for knee osteoarthritis: A protocol for a triple-blinded randomized controlled trial. BMC Complement Altern Med, 2018; 18:157.
